EUVIMEDEUVIMED entdecken
Crossref

Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma

Yanguang Yang, Yuting Gao, Yi Gong, Junlan Lu, Shenghao Li, Yajun Xiong, Yuman Zhang, Dan Wang, Peng Gong, Yunfeng Li, Xinli Shi

Acta Histochemica · 2024

DOI: 10.1016/j.acthis.2024.152171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Histochemica, 2024. Verfasst von Yanguang Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China; Hebei Key Laboratory of Chinese Medicine…. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Hepatocellular, Artemisinins, Liver Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Hepatocellular carcinoma, characterized by high mortality rates, often exhibits limited responsiveness to conventional treatments such as surgery, radiotherapy, and chemotherapy. Therefore, identifying a sensitizer for cisplatin has become crucial. Dihydroartemisinin, known for its potent role of tumor treatment, arises as a prospective candidate for cisplatin sensitization in clinical settings. METHODS: A mouse model of liver tumor was established through chemical induction of DEN/TCPOBOP. Upon successful model establishment, ultrasound was employed to detect tumors, Hematoxylin and eosin staining was conducted for observation of liver tissue pathology, and ELISA was utilized to assess cytokine changes (IFN-γ, IL-2, IL-4, IL-10, TGF-β, IL-1β, CCL2, and CCL21) in peripheral blood, para-tumor tissues, and tumor tissues. The infiltration of CD8+T cells and macrophages in tumor tissue sections was detected by immunofluorescence. RESULTS: Dihydroartemisinin combined with cisplatin obviously restrained the growth of liver tumors in mice and improved the weight and spleen loss caused by cisplatin. Cisplatin treatment of liver tumor mice increased the content of CCL2 and the number of macrophages in tumor tissues and promoted the formation of an immunosuppressive microenvironment. The combination therapy decreased the content of TGF-β in tumor tissues while increasing CCL2 levels in para-tumor tissues. Both combination therapy and cisplatin alone increased the number of CD8+T cells in tumor tissue, but there was no difference between them. CONCLUSION: Dihydroartemisinin combined with cisplatin obviously prevented the deterioration of liver tumor in hepatocellular carcinoma mice and improve the therapeutic effect of cisplatin by improving the immunosuppressive microenvironment induced by cisplatin. Our findings provide a theoretical basis for considering dihydroartemisinin as an adjuvant drug for cisplatin in the treatment of hepatocellular carcinoma in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinCarcinoma, HepatocellularArtemisininsLiver NeoplasmsTumor MicroenvironmentAnimalsMiceMaleAntineoplastic AgentsChemokine CCL2Cytokines

Stichwörter der Autor:innen

CisplatinCytokineDihydroartemisininHepatocellular carcinomaImmunosuppressive microenvironment

Substanzen

CisplatinartenimolArtemisininsAntineoplastic AgentsChemokine CCL2Cytokines

Autor:innen und Institutionen

  • Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China; Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chine…
  • Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan 030000, China.
  • Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
  • Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chinese Medicine, Shijiazhuang 050200, China. Electronic address: fengzong117@aliyun.com.
  • Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang 050200, China; Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan 030000, Chi…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, Y., Gao, Y., Gong, Y., Lu, J., Li, S., Xiong, Y., Zhang, Y., Wang, D., Gong, P., Li, Y., & Shi, X. (2024). Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma. Acta Histochemica. https://doi.org/10.1016/j.acthis.2024.152171

Vancouver

Yang Y, Gao Y, Gong Y, Lu J, Li S, Xiong Y, et al. Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma. Acta Histochemica. 2024. doi:10.1016/j.acthis.2024.152171

BibTeX
@article{Yang2024,
  author = {Yang, Yanguang and Gao, Yuting and Gong, Yi and Lu, Junlan and Li, Shenghao and Xiong, Yajun and Zhang, Yuman and Wang, Dan and Gong, Peng and Li, Yunfeng and Shi, Xinli},
  title = {Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma},
  journal = {Acta Histochemica},
  year = {2024},
  doi = {10.1016/j.acthis.2024.152171}
}
Kostenlos starten →